Science selects Renakapavir 'Innovation of the Year' for preventing HIV infection for 6 months with a single shot
Dec 13, 2024
Science, a global scientific journal, has selected lenacapavir (lenacapavir), a groundbreaking HIV infection treatment, and related studies for the '2024 Innovation of the Year'.
Renacapavir, an anti-retroviral drug developed by Gilead, is an injection that prevents human immunodeficiency virus (HIV) infection for six months with a single dose.
Science explained that the drug was 100% preventive in clinical trials for African adolescent girls and women and 99.9% in various genders on multiple continents. He also said that the secret to this effect came from groundbreaking research on HIV's capsid protein, which protects viral genetic material. Renacapavir acts as a mechanism to block the major steps in viral replication by hardening capsid proteins. Such a mechanism was once considered impractical, but the success of renacapavir is expected to inspire the treatment of other viral diseases.
Science explained that lenacapavir was initially developed as a rescue therapy for patients who developed resistance to other drugs, but lenacapavir, which was developed in the form of a long-lasting injection, has now established itself as a drug that can be a game changer in HIV prevention.
Meanwhile, Renacapavir is expected to be approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA) by next year.
Renacapavir, an anti-retroviral drug developed by Gilead, is an injection that prevents human immunodeficiency virus (HIV) infection for six months with a single dose.
Science explained that the drug was 100% preventive in clinical trials for African adolescent girls and women and 99.9% in various genders on multiple continents. He also said that the secret to this effect came from groundbreaking research on HIV's capsid protein, which protects viral genetic material. Renacapavir acts as a mechanism to block the major steps in viral replication by hardening capsid proteins. Such a mechanism was once considered impractical, but the success of renacapavir is expected to inspire the treatment of other viral diseases.
Science explained that lenacapavir was initially developed as a rescue therapy for patients who developed resistance to other drugs, but lenacapavir, which was developed in the form of a long-lasting injection, has now established itself as a drug that can be a game changer in HIV prevention.
Meanwhile, Renacapavir is expected to be approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA) by next year.
This article was translated by Naver AI translator.
